By Katherine Hamilton
Repare Therapeutics plans to find a partner before moving forward with developing a possible treatment for cancer as it aims to extend its cash runway into 2027.
The oncology company said Thursday it will find a partner before it proceeds with planned and regulatory-supported pivotal development of lunresertib and camonsertib, which together are meant to treat gynecological cancer.
Repare is also reorganizing its resources and clinical portfolio to focus on advancing the Phase 1 clinical programs of its tumor treatments RP-1664 and RP-3467.
Savings from late-stage clinical funding and planned layoffs are expected to extend the company's cash runway into the mid-2027, the company said.
In August, Repare said it planned to cut about a quarter of its workforce as part of strategic move to refocus efforts on its lunresertib, camonsertib, RP-1664 and RP-3467 products. It anticipated the layoffs will generate about $15 million in annual savings.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 09, 2025 17:00 ET (22:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.